ALLMedicine™ Liver Transplants Center

May 17th, 2021 - Antiviral therapy with or without hepatitis B immune globulin (HBIG) is a common strategy for the prevention of hepatitis B virus (HBV) reinfection. But there is no consensus on management protocols, and long-term data are relatively rare on recur...

May 12th, 2021 - Despite record-breaking numbers of liver transplants (LTs) performed in the United States in each of the last 7 years, many patients remain on the wait list as the demand for LT continues to exceed the supply of available donors. The emergence of ...

May 12th, 2021 - Better understanding of how to utilize donation after circulatory death (DCD) liver grafts has resulted in improved national outcomes and expansion in the number of DCD liver transplants (LTs). This improvement has been driven by better donor and ...

May 1st, 2021 - Donor age is an important predictor for liver transplant recipients. Studies have not fully explored its impact on transplant outcomes in hepatocellular carcinoma (HCC) patients as well as its involvement in tumor recurrence. HCC patients who rece...

Apr 22nd, 2021 - More than 13,000 patients are added to the waitlist for life saving liver transplants across the United States each year. Despite the need, demand for liver allografts outpaces supply with nearly 1200 patients dying while awaiting a liver transpla...

Dec 31st, 2012 - Liver disease is the twelfth commonest cause of mortality in adults in the United States, resulting in 34,000 deaths annually from cirrhosis. 7 In addition, the rising incidence of HCC in the United States is reflected in an increasing number of de.

May 17th, 2021 - Antiviral therapy with or without hepatitis B immune globulin (HBIG) is a common strategy for the prevention of hepatitis B virus (HBV) reinfection. But there is no consensus on management protocols, and long-term data are relatively rare on recur...

May 12th, 2021 - Despite record-breaking numbers of liver transplants (LTs) performed in the United States in each of the last 7 years, many patients remain on the wait list as the demand for LT continues to exceed the supply of available donors. The emergence of ...

May 12th, 2021 - Better understanding of how to utilize donation after circulatory death (DCD) liver grafts has resulted in improved national outcomes and expansion in the number of DCD liver transplants (LTs). This improvement has been driven by better donor and ...

May 1st, 2021 - Donor age is an important predictor for liver transplant recipients. Studies have not fully explored its impact on transplant outcomes in hepatocellular carcinoma (HCC) patients as well as its involvement in tumor recurrence. HCC patients who rece...

Apr 27th, 2021 - Mycophenolate mofetil for injection is indicated for the prophylaxis of organ rejection, in recipients of allogeneic kidney [see Clinical Studies (14.1)], heart [see Clinical Studies (14.2)] or liver transplants [see Clinical Studies (14.3)], in c...

Aug 19th, 2020 - NEW YORK (Reuters Health) - Most patients will develop liver fibrosis after their Fontan procedure, and many will require heart-liver transplants, according to a new review. "Fontan-associated liver disease (FALD) is underdiagnosed," Dr. Juliet Em...

May 11th, 2020 - NEW YORK (Reuters Health) - The COVID-19 pandemic has led to a sharp drop in organ transplantation in the United States and France, a new report in The Lancet shows. From late February to early April, deceased donor transplantations fell by 51.1% ...

Apr 1st, 2020 - In liver transplant recipients or patients with autoimmune hepatitis on immunosuppressive therapy, acute cellular rejection or disease flare should not be presumed in the face of active coronavirus disease 2019 (COVID-19), according to the America.

Dec 16th, 2019 - (Reuters) - Gilead Sciences Inc said on Monday all combinations of its three drugs to treat NASH were unsuccessful in a mid-stage study, the latest failure in a string of trials seeking to develop the first approved treatment for the fatty liver d...

Nov 6th, 2019 - Liver transplant for the three predominant autoimmune liver diseases – primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis – has been known to have favorable outcomes overall, but little evidence comparing cholang.